Q2 2023 · 13F-HR
TCG Crossover Management, LLCholdings as filed
Filed 2023-08-14 · accession 0001214659-23-011170
$609.8M
Reported value
22
Positions
2023-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 46583P102 | — | IVERIC BIO INC | $96.3M | 15.8% | 2,448,829 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $75.7M | 12.4% | 23,589,779 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $66.7M | 10.9% | 5,631,042 | Common | SOLE |
| H9060V101 | — | VECTIVBIO HOLDING AG | $52.9M | 8.68% | 3,113,600 | Common | SOLE |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $37.8M | 6.19% | 2,201,274 | Common | SOLE |
| 45114M109 | — | ICOSAVAC, INC | $36.8M | 6.03% | 3,703,704 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $34.6M | 5.68% | 149,917 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $33.9M | 5.56% | 1,989,103 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS, INC | $30.6M | 5.01% | 3,395,495 | Common | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES, INC | $26.8M | 4.39% | 815,724 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS, INC | $18.6M | 3.04% | 1,650,150 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $15.1M | 2.47% | 1,423,642 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $14.5M | 2.39% | 350,000 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT, INC | $12.4M | 2.04% | 654,853 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $11.6M | 1.90% | 2,104,875 | Common | SOLE |
| 037326105 | ANTX | AN2 Therapeutics, Inc. | $11.0M | 1.80% | 1,289,320 | Common | SOLE |
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $8.9M | 1.45% | 584,955 | Common | SOLE |
| N5749R100 | 2GH | MERUS BV | $7.9M | 1.30% | 300,000 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO, INC | $6.3M | 1.03% | 486,795 | Common | SOLE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $5.5M | 0.90% | 529,839 | Common | SOLE |
| 12529R107 | CCCC | C4 THERAPEUTICS, INC. | $3.5M | 0.58% | 1,276,574 | Common | SOLE |
| 02083G100 | NVLSEUR | ALPINE IMMUNE SCIENCES INC | $2.6M | 0.43% | 253,069 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.